Expression patterns of *HMGA2* in the placenta during pregnancy

**Lars Burchardt¹, Andrea Gottlieb¹, Burkhard M. Helmke², Werner Wosniok³,
Wolfgang Kuepker⁴, and Jörn Bullerdiek^{1,5§}**

¹Center for Human Genetics, University of Bremen, Leobener Str. ZHG, 28359 Bremen, Germany

²Institute for Pathology, Elbe Clinic Stade-Buxtehude, 21682 Stade, Germany

³Institute of Statistics, University of Bremen, Linzer Str. 4, 28359 Bremen, Germany

⁴Wolfgang Kuepker, IVF Baden Baden – IVF Life Group, Beethovenstraße 2, 76530 Baden-Baden, Germany

⁵Institute for Medical Genetics, University of Rostock, University Medicine, 18057 Rostock, Germany

§Corresponding author: joern.bullerdiek@med.uni-rostock.de

Email addresses:

LB: elars@gmx.net

BMH: burkhard.helmke@elbekliniken.de

WW: wwosniok@math.uni-bremen.de

AG: a.gottlieb@uni-bremen.de

Keywords: placenta, HMGA2, gestational age, development, abortion

Abstract

Background

High-mobility group AT-hook 2 (HMGA2) expression can be detected in many embryonic and fetal tissues but becomes down-regulated during postnatal life except for many benign and malignant tumors. In the latter case, its expression has been correlated with epithelial-mesenchymal transition and invasive growth. The placenta contributes essentially to proper development of the embryo and the fetus. In a tumor-like manner it shows rapid invasive growth during the first weeks of gestation. To address the possible role of HMGA2 during placental development, we have measured its expression throughout the prenatal period and in term placentae by mRNA quantification as well as by immunohistochemistry.

Methods

Expression of *HMGA2* and *HPRT* was measured on 89 fetal placentas, encompassing calendar gestational age of five to 41 weeks, using quantitative real time-PCR. In eleven cases in addition immunohistochemistry was used to determine the localization of HMGA2 and to compare with data obtained by quantitative real time-PCR.

Results

The expression of *HMGA2* was found to be inversely correlated with gestational age ($p < 0.001$). For the first part of the first trimester the level of *HMGA2* is high. After that the expression shows a decline down to a baseline level where it remains until birth. HMGA2 protein was mainly detected in the nuclei of the stromal cells in the placental villi.

Conclusions

During pregnancy, the expression of *HMGA2* follows a non-linear pattern of decrease. In the first trimester, from two to three weeks after the implantation of the conceptus until the blood supply is established (hypoxic phase), the expression is high, indicating a critical role during early development and in the control of its invasive behavior, respectively.

Introduction

Human high-mobility group AT-hook protein 2 belongs to a family of non-histone chromatin proteins encoded by two genes, *HMGA1* and *HMGA2*. Due to alternative splicing, there are four known proteins (HMGA1a, HMGA1b, HMGA1c, and HMGA2) [reviewed in [1]]. All HMGA proteins are architectural transcription factors and contain three DNA-binding domains called AT-hooks and an acidic carboxy-terminal tail. As such, they do not have an intrinsic transcription factor capacity but rather enhance or silence transcription through a change in chromatin structure and interaction with nuclear proteins [reviewed in [2,3]. They

play a key role in stem cell renewal, growth and development of tissues, and the differentiation of cells [4-6]. As to the expression of HMGA2 in mammalian cells and tissues, three fields can be distinguished: First, in contrast to embryonic and fetal development its expression is not detectable in most adult tissues and cells [7-10] with few exceptions as e.g. some types of mesenchymal stem cells [11], spermatocytes, and spermatides [12] and constitutional knock-out of *HMGA2* is associated with a pygmy phenotype in mice [13]. Secondly, once activated by chromosomal translocations, it apparently causally can contribute to the growth of a variety of benign tumors of adult tissues such as uterine leiomyomas, lipomas, pulmonary chondroid hamartomas, and pleomorphic adenomas of the salivary glands [14-16]. Thirdly, an overexpression of HMGA2 occurring independent of chromosomal translocations affecting its gene locus and surrounding sequences was detected in numerous types of cancers (reviewed in [1,17,18]) where its expression is usually associated with a higher degree of malignant behavior and worse prognosis, respectively [19-27]. Accordingly, the expression of HMGA2 is considered being a promising universal tumor marker for prognostics [26].

The placenta is the only normal human organ infiltrating surrounding tissue albeit as a rule in a tightly restricted manner following mechanisms that are not fully understood until today. It serves as the connection between mother and embryo or fetus providing nutrients and oxygen for the developing child. About six days after fertilization the blastocyst starts implantation into the maternal uterus and placentation. Five weeks after conception the basic structure of the placenta has formed. To support the developing embryo and fetus it continues to grow throughout gestation. Disturbances of the depth of infiltration are associated with serious problems such as preeclampsia and placenta accrete or percreta.

The detection of *HMGA2* expression in the placenta dates back to 1996 [8]. To detect *HMGA2* mRNA, several embryonal/fetal tissues of a gestational age between eight to twelve weeks and samples of the maternal and the fetal part of a placenta (36th weeks of pregnancy) were analyzed by RT-PCR. The experiments yielded positive results for the embryo but negative findings for the placenta. In an investigation by Hirning-Folz *et al.* [10] RNA in situ hybridization was used on mouse embryo sections for detection of *HMGA2* mRNA. Fetal placenta showed reduced expression compared to nearly all parts of the embryo at a developmental stage of 9.5. *HMGA2* mRNA was also detected by RT-PCR but not by northern blot analysis in three human fetuses of 19 to 22 weeks estimated gestational age by Gattas *et al.* [28]. Genbacev *et al.* [29] identified the chorionic

mesoderm as a niche for human trophoblastic progenitor cells that support placental growth. *HMGA2* was found to be one of the factors associated with the self-renewal or differentiation of these cells.

The aim of the present study was to investigate temporal and spatial expression patterns of *HMGA2* in the human placenta aimed at insights into the role of *HMGA2* in the development of this organ and into a possible use of this molecule as a biomarker indicating disturbances of proper implantation and placenta development.

Methods

Tissue specimens and RNA isolation

Formalin-fixed paraffin-embedded (FFPE) tissue samples were collected at the Institute for Pathology, Elbe Clinic Stade-Buxtehude, Germany. Pathological examinations were performed after haematoxylin and eosin staining of the samples. Six to eight sections of 5 µm for each sample were used for isolation of total RNA. Isolations were performed using the innuPREP Micro RNA Kit (Analytik Jena, Jena, Germany) according to the manufacturer's instructions with the following modifications: Lysis of the paraffin sections preceding RNA isolation was conducted using TLS-Lysis Solution and Proteinase K from the innuPREP DNA Micro Kit (Analytik Jena) without prior deparaffinization. Sections were incubated for 1 h at 60°C and 15 min at 80°C.

cDNA-synthesis and quantitative real-time RT-PCR

RNAs were reverse-transcribed into cDNA by M-MLV Reverse Transcriptase (Invitrogen, Karlsruhe, Germany). Quantitative real-time PCR (qRT-PCR) was performed using the Applied Biosystems 7300 sequence detection system according to TaqMan Gene Expression Assay Protocol (Applied Biosystems, Darmstadt, Germany) in 96-well microtiter plates with a total volume of 20 µl. In the case of the TaqMan gene expression assay for *HMGA2* (assay number Hs00171569, Applied Biosystems, Foster City, USA), each reaction consisted of 2 µl of cDNA reverse transcribed from 25 ng of total RNA, 10 µl of TaqMan Universal PCR Master Mix (Applied Biosystems), 1 µl of TaqMan assay, and 7 µl of ddH₂O. For the *HPRT* assay, using *HPRT* FP and *HPRT* RP primers [30], each reaction consisted of 2 µl of cDNA reverse transcribed from 25 ng of total RNA, 10 µl of TaqMan Universal PCR Master Mix, 600 nM (1.2 µl) of forward and reverse primers, and 200 nM (0.2 µl) of probe [30] and 5.4 µl of ddH₂O. Thermal cycling conditions were 2 min at 50°C followed by 10 min at 95°C, 50 cycles at 95°C for 15 s and 60°C for 1 min. For

each sample a negative control of the previous cDNA synthesis (missing reverse transcriptase) and for each plate a non-template control of amplification and a non-template control of previous cDNA synthesis were included in each run. Sequence Detection Software 1.2.3 (Applied Biosystems) was used to analyze data. All testing reactions were performed in triplicate. *HPRT* was used as endogenous control as it has previously been shown to be stably expressed in human fetal placenta [31-33]. As recommended for FFPE samples [34], the fragment sizes amplified by both assays were small, ranging between 65 and 80 bp. A validation of these values was performed via gel electrophoresis of the PCR product (data not shown). When applying the comparative C_T method, the sample with the lowest value was used as calibrator.

Immunohistochemical analysis

Slides utilized for the immunohistochemical analysis were produced using consecutive sections directly adjacent to those for the qRT-PCR investigation. Immunohistochemical staining for HMGA2 (rabbit polyclonal anti-HMGA2-P3, Biocheck, Forster City, USA) was performed using a detection kit (DAKO, Glostrup, Denmark) and a semi-automated stainer (DAKO TechMate) according to the specifications of the manufacturer. For antigen retrieval the slides were treated in a PT Link module (DAKO) using the EnVision™ FLEX Target Retrieval Solution, low pH (DAKO). The antibody dilution used was 1:500.

A FFPE sample from a uterine leiomyoma carrying a *HMGA2* rearrangement leading to its overexpression served as positive control whereas negative control was performed by omission of the primary antibody. Staining extent was classified as negative, very weak, weak, moderate, and strongly positive, respectively.

Statistical analysis

The two-sided Wilcoxon rank sum test to compare averages from two independent groups was used. Relationships between two observed or measured amounts were quantified by linear regression or by a nonparametric spline model. If the latter turned out to have a significantly better fit, models were compared by the likelihood ratio test. A *p*-value of less than 0.05 was considered significant, a *p*-value below 0.001 was deemed highly significant. Statistical calculations were done using the R package, version 2.3.2 [35].

Ethics Statement

All samples investigated were initially taken for diagnostic purposes and only secondarily used for the present study. Samples were de-identified before their use in this study, in line

with the rules of the Helsinki declaration. The study was approved by the local ethics committee (Aerztekammer Bremen: reference number 371).

Results

qRT-PCR analysis for the expression of *HMGA2* mRNA

Eighty-nine samples of human fetal placenta were tested for the expression of *HMGA2* mRNA (table 1A and 1B). Eighty-five were collected after termination of the pregnancy or abortion, respectively. In three cases no information was available about the type of abortion. In addition, four specimens from term placentae were examined as well. The placenta samples showed a relative expression ranging from 1 to 498 (fig. 1).

Overall, a strong decline of the expression of *HMGA2* was noted with gestational age. For all placenta samples, the correlation coefficient was 0.653 ($p = 2.37 \times 10^{-12}$) (fig. 2). When the analysis was restricted to the specimens after induced abortion (IA) and after delivery (AD), the r -value was 0.889 ($p = 3.88 \times 10^{-9}$). The samples collected after spontaneous abortion (SA) showed a correlation coefficient of 0.431 ($p = 1.30 \times 10^{-4}$). The relation between gestational age and *HMGA2* expression did not significantly differ between these groups ($p = 0.095$, likelihood ratio test).

HMGA2 mRNA levels from samples taken during the first trimester of pregnancy were significantly higher than those of the second and third trimester ($p = 3.82 \times 10^{-7}$, Wilcoxon signed rank test). Using the same test, significant differences were also found within the SA subgroup ($p = 0.00257$) and within the IA and AD joint subgroups ($p = 1.98 \times 10^{-5}$). Overall, a relatively wide ranging but overall high level of expression was observed up to 13 weeks (calendar gestational age (GA)). After that, the level of expression strongly declined up to a CGA of 28 weeks where it finally reached a steady value for the rest of the pregnancy. In specimens of induced abortions, the observed drop was more pronounced and happened earlier, at around nine weeks of gestation.

Pathological examinations of the specimens after haematoxylin and eosin staining revealed a considerable percentage of maternal decidua in some of the samples (see also table 1). After immunohistochemical analysis (see also below), the decidua was found to be *HMGA2* negative (data not shown). Nevertheless, omitting this data does not change the general expression patterns of *HMGA2* during pregnancy.

Immunohistological analysis

Eleven samples were investigated for the presence and localization of HMGA2 by immunohistochemical analysis. In general, samples from early gestation (eight to ten weeks GA) showed intense signals (fig. 3A) with the strongest staining visible in the nuclei of the stroma cells and slightly less intense signals in the cytoplasm of the trophoblast. In contrast, samples from GA between 19 and 41 weeks showed only weak to very weak signals (fig. 3B). Overall, the results from the immunostaining are in concordance with those from the qRT-PCR, except for two outliers. Decidual tissue as found in some of the samples turned out to lack detectable expression of HMGA2 by immunostaining.

Discussion

A highly significant decrease of the level of *HMGA2* mRNA with increasing CGA was found in this study. The level of *HMGA2* declines towards the end of the first trimester with an apparently stable but low level reached around week 28. In samples from induced abortions, the *HMGA2* level dropped around the ninth week of CGA. In induced and spontaneous abortions as one group, the decrease is less steep and takes place several weeks later. For the specimens collected after spontaneous abortion it is conceivable that the underlying cause of the abortion had affected the development of the placenta and the expression of *HMGA2*. In addition, the embryo or fetus might have died a varying period of time before abiosis of the placenta [36,37]. Therefore, despite a smaller sample size, more reliable results may be obtained from the group of specimens gathered after induced abortion or after birth. The stable level of *HMGA2*-expression detected in samples from the third trimester as well differs from the analysis by Rogalla *et al.* [8] revealing an absence of *HMGA2*-expression in term placentae. A possible explanation is the higher sensitivity of qRT-PCR compared to conventional RT-PCR.

HMGA2 is known to participate in the proliferation of tissues by upregulation of genes involved in cell proliferation and invasion [reviewed in [1,38]. Therefore, the results presented in this study are in accordance with those published by Sitras *et al.* [39] who tested more than 29.000 genes in human placentas. Applying microarray analysis, they found that genes involved in cell proliferation, differentiation, and angiogenesis are upregulated in human first trimester placentae. In this latter study, the expression of *HMGA2* was not tested.

As demonstrated here, high *HMGA2* expression correlates with the uterine low oxygen environment in early pregnancy. As a result of trophoblast invasion into the maternal

decidua, spiral arteries are plugged during the first 7 to 8 weeks of pregnancy [reviewed in [40]]. Filtrated plasma enriched with secretions from the endometrial glands can be found in the placental intervillous space, providing histiotrophic nutrition [41]. A low oxygen environment has been shown to be necessary for the proliferation of cytotrophoblast cells [42,43]. Around week 7 to 8 of gestation (week 9 to 10 CGA), maternal uterine circulation to the placenta begins [44], resulting from disintegration of spiral arterial plugs [45], indicating the starting of haemotrophic nutrition of the fetus, which is reaching its full function from week 12 of gestation on. The increasing oxygen level coincides with the decrease of *HMGA2* expression.

Spatially and temporally accurate proliferation and invasion of trophoblast cells are crucial for an undisturbed pregnancy. Superficial implantation of the placenta leading to poor placental and uterine perfusion is characteristic for preeclampsia [46], reviewed in [47]. Preeclampsia affects 2 % to 8 % of all pregnancies [48] and is the cause of direct maternal death in 16 % [49] to 39 % of cases [50]. The only treatment of this serious medical condition is planned preterm delivery. Preeclampsia is not yet fully understood and there are few markers for diagnosis [51]. In combination with oxidative stress of the placenta [reviewed in [36]], several transcription factors involved in the proliferation and differentiation of the trophoblast have been detected to contribute to an elevated risk of preeclampsia [52-55]. For some proteins a significantly higher expression has been shown in early gestation [53,54,56], similar to the results for *HMGA2*. While symptoms of preeclampsia do not appear before the 20th week of gestation, it seems to result from earlier changes of proliferation and differentiation of the trophoblast that play a key role in the implantation of the embryo during low placental oxygenation [reviewed in [57]]. In this study, in case number 89 a severe form of preeclampsia leading to a premature delivery at the gestational age of 32 weeks (see also table 1) was diagnosed. The measured value for *HMGA2* was within the normal range of probes of this late stage of pregnancy. In case of a correlation between *HMGA2* and preeclampsia, a deviation might be restricted to the first trimester since in that period of time the proliferation and invasion of the trophoblast determines whether an elevated risk for preeclampsia will exist. A similar situation has been proposed by Jeon *et al.* [51] for IMUP-2. They suggest an association of this protein with preeclampsia but in term placentae their findings do not reveal differences for patients with or without preeclampsia.

Whereas shallow infiltration of the trophoblast is a sign for preeclampsia, overly deep infiltration indicates another obstetric complication: placenta accreta (including the closely related forms of increta and percreta). This severe complication during pregnancy has

been associated with decidual deficiency and an overinvasive trophoblast (reviewed in [58]). Placenta accreta accounts for about 1 % of maternal mortality in the USA [36] and approximately 5 % of the women with this complication die [59-61]. In addition, fetal deaths occur in almost 26 % of the cases [61]. Since the 1970s the incidence has risen from one in approximately 4,000 deliveries to one in 333 [59,60,62,63]. The reasons are unknown, making further investigations necessary. Since there is no definitive method [64] to detect this complication before birth, a possible test would be of high interest. However, aberrant *HMGA2* expression cannot be determined by a screening procedure using non-invasive methods. Further investigations are needed to check if determination of *HMGA2* or its mRNA in maternal serum might be a reliable method.

By immunostaining it became apparent that *HMGA2* is strongly expressed in the stroma cells of the placental villi. Positive staining mainly was noted in the nucleus, but in a lesser concentration also observed in the cytoplasm of the trophoblast. This pattern is significantly different from that of *HMGA1* [65] found exclusively in the trophoblast cells. This suggests different roles for the two members of the *HMGA* family. The results of this study are in concordance with those from Genbacev *et al.* [66] who also found *HMGA2* in the villi as well as a change from nuclear to cytoplasmatic location. In general, *HMGA* proteins are considered nuclear proteins [1], even though cytoplasmatic expression of *HMGA1* has been reported before [65]. Thus, in the majority of papers only nuclear immunoreactivity for *HMGA2* was noted [67,68].

Funding

There was no external funding for this study.

Authors' contributions

Study design: LB, JB

Provision of sample, immunostaining for *HMGA2*, clinical workout: BMH

Molecular genetic studies: LB

Pathological determination of samples: BMH, AG

Immunohistochemical analysis: BMH, LB, AG

Statistical analysis and interpretation of data: WW, LB, WK, JB

Writing of manuscript: LB, AG, WK, JB

All authors have read and approved the final manuscript.

Declaration of competing interests

The authors declare that they have no competing interests (see attachment).

Relevant ethical guidelines

All relevant ethical guidelines have been followed, all necessary IRB and/or ethics committee approvals have been obtained, all necessary patient/participant consent has been obtained and the appropriate institutional forms archived.

References

1. Cleynen I, Van de Ven WJ: The HMGA proteins: a myriad of functions (Review). *Int J Oncol* 32:289-305, 2008
2. Reeves R, Beckerbauer L: HMGI/Y proteins: flexible regulators of transcription and chromatin structure. *Biochim Biophys Acta* 1519:13-29, 2001
3. Reeves R: Molecular biology of HMGA proteins: hubs of nuclear function. *Gene* 277:63-81, 2001.
4. Zhou X, Chada K: HMGI family proteins: architectural transcription factors in mammalian development and cancer. *Keio J Med* 47:73-77, 1998
5. Chieffi P, Battista S, Barchi M, et al: HMGA1 and HMGA2 protein expression in mouse spermatogenesis. *Oncogene* 21:3644-3650, 2002
6. Caron L, Bost F, Prot M, et al: A new role for the oncogenic high-mobility group A2 transcription factor in myogenesis of embryonic stem cells. *Oncogene* 24:6281-6291, 2005
7. Chiappetta G, Avantiaggiato V, Visconti R, et al: High level expression of the HMGI (Y) gene during embryonic development. *Oncogene* 13:2439-2446, 1996
8. Rogalla P, Drechsler K, Frey G, et al: HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. *Am J Pathol* 149:775-779, 1996
9. Zhou X, Benson KF, Przybysz K, et al: Genomic structure and expression of the murine Hmgi-c gene. *Nucleic Acids Res* 24:4071-4077, 1996
10. Hirning-Folz U, Wilda M, Rippe V, et al: The expression pattern of the Hmgic gene during development. *Genes Chromosomes Cancer* 23:350-357, 1998
11. Markowski DN, Winter N, Meyer F, et al: p14Arf acts as an antagonist of HMGA2 in senescence of mesenchymal stem cells-implications for benign tumorigenesis. *Genes Chromosomes Cancer* 50:489-498, 2011
12. Kloth L, Gottlieb A, Helmke B. *et al*. HMGA2 expression distinguishes between different types of postpubertal testicular germ cell tumour. *J Pathol: Clin Res* 1:239-251, 2015
13. Zhou X, Benson KF, Ashar HR, et al: Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. *Nature* 376:771-774, 1995
14. Ashar HR, Fejzo MS, Tkachenko A, et al: Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. *Cell* 82:57-65, 1995
15. Schoenmakers EF, Wanschura S, Mols R, et al: Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. *Nat Genet* 10:436-444, 1995

16. Gross KL, Neskey DM, Manchada N, et al: HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies. *Genes Chromosomes Cancer* 38:68-79, 2003
17. Fusco A, Fedele M: Roles of HMGA proteins in cancer. *Nat Rev Cancer* 7:899-910, 2007
18. Fedele M, Fusco A: HMGA and cancer. *Biochim Biophys Acta* 1799:48-54, 2010
19. Rogalla P, Drechsler K, Kazmierczak B, et al: Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. *Mol Carcinog* 19:153-156, 1997
20. Rommel B, Rogalla P, Jox A, et al: HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. *Leuk Lymphoma* 26:603-607, 1997
21. Helmke BM, Markowski DN, Meyer A, et al: The expression of HMGA2 varies strongly among colon carcinomas. *Anticancer Res* 32:1589-1593, 2012
22. Fehr A, Meyer A, Heidorn K, et al: A link between the expression of the stem cell marker HMGA2, grading, and the fusion CRTC1-MAML2 in mucoepidermoid carcinoma. *Genes Chromosomes Cancer* 48:777-785, 2009
23. Belge G, Meyer A, Klemke M, et al: Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. *Genes Chromosomes Cancer* 47:56-63, 2008
24. Takahashi T, Kawaji H, Murakawa Y, et al: Significance of HMGA2 expression as independent poor prognostic marker in perihilar and distal cholangiocarcinoma resected with curative intent. *Eur J Surg Oncol* S0748-7983(20)30697-1, 2020
25. Meyer B, Loeschke S, Schultze A, et al: HMGA2 overexpression in non-small cell lung cancer. *Mol Carcinog* 46:503-511, 2007
26. Pham YTH, Utuama O, Thomas CE, et al: High mobility group A protein-2 as a tumor cancer diagnostic and prognostic marker: a systematic review and meta-analysis. *Eur J Cancer Prev* 29:565-581, 2020
27. Guo HH, Wang YZ, Zhang ZK, et al: High mobility group AT-hook 2 promotes tumorigenicity of pancreatic cancer cells via upregulating ANLN. *Exp Cell Res* 393:112088, 2020
28. Gattas GJ, Quade BJ, Nowak RA, et al: HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. *Genes Chromosomes Cancer* 25:316-322, 1999
29. Genbacev O, Donne M, Kapidzic M, et al: Establishment of human trophoblast progenitor cell lines from the chorion. *Stem Cells* 29:1427-1436, 2011

30. Specht K, Richter T, Muller U, et al: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. *Am J Pathol* 158:419-429, 2001
31. Meller M, Vadachkoria S, Luthy DA, et al: Evaluation of housekeeping genes in placental comparative expression studies. *Placenta* 26:601-607, 2005
32. Kanda A, Stambolian D, Chen W, et al: Age-related macular degeneration-associated variants at chromosome 10q26 do not significantly alter ARMS2 and HTRA1 transcript levels in the human retina. *Mol Vis* 16:1317-1323, 2010
33. Khan MA, Mittal S, Kumar S, et al: Quantitative analysis of six gene products as candidate markers of early placental villi development in the human. *Indian J Physiol Pharmacol* 54:299-308, 2010
34. Antonov J, Goldstein DR, Oberli A, et al: Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. *Lab Invest* 85:1040-1050, 2005
35. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna. Austria; 2015 [<http://www.R-projekt.org/>]. date accessed 27-01-2017.
36. Burton GJ: Oxygen, the Janus gas; its effects on human placental development and function. *J Anat* 215:27-35, 2009
37. Blaas HG, Eik-Nes SH, Bremnes JB: The growth of the human embryo. A longitudinal biometric assessment from 7 to 12 weeks of gestation. *Ultrasound Obstet Gynecol* 12:346-354, 1998
38. Hammond SM, Sharpless NE: HMGA2, microRNAs, and stem cell aging. *Cell* 35:1013-1016, 2008
39. Sitras V, Fenton C, Paulssen R, et al: Differences in gene expression between first and third trimester human placenta: a microarray study. *PLoS One* 7:e33294, 2012
40. Burton GJ, Jauniaux E, Charnock-Jones DS: The influence of the intrauterine environment on human placental development. *Int J Dev Biol* 54:303-312, 2010
41. Burton GJ, Watson AL, Hempstock J, et al: Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. *J Clin Endocrinol Metab* 87:2954-2959, 2002
42. Genbacev O, Joslin R, Damsky CH, et al: Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. *J Clin Invest* 97:540-550, 1996
43. Ali KZ: Stereological study of the effect of altitude on the trophoblast cell populations of human term placental villi. *Placenta* 18:447-450, 1997

44. Burton GJ, Jauniaux E, Watson AL: Maternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: the Boyd collection revisited. *Am J Obstet Gynecol* 181:718-724, 1999
45. Weiss G, Sundl M, Glasner A, et al. The trophoblast plug during early pregnancy: a deeper insight. *Histochem Cell Biol* 146:749-756, 2016
46. Redline RW, Patterson P: Pre-eclampsia is associated with an excess of proliferative immature intermediate trophoblast. *Hum Pathol* 26:594-600, 1995
47. Al-Jameil N, Aziz Khan F, Fareed Khan M, et al: A brief overview of preeclampsia. *J Clin Med Res* 6:1-7, 2014
48. Duley L: The global impact of pre-eclampsia and eclampsia. *Semin Perinatol* **33**:130-137, 2009
49. Clark SL, Belfort MA, Dildy GA, et al: Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. *Am J Obstet Gynecol* 199:36.e1-5; discussion 91-2. e7-11, 2008
50. Schutte JM, Steegers EA, Schuitemaker NW, et al: Rise in maternal mortality in the Netherlands. *BJOG* 117:399-406, 2010
51. Jeon SY, Lee HJ, Park JM, et al: Increased immortalization-upregulated protein 2 (IMUP-2) by hypoxia induces apoptosis of the trophoblast and pre-eclampsia. *J Cell Biochem* 110:522-530, 2010
52. Janatpour MJ, McMaster MT, Genbacev O, et al: Id-2 regulates critical aspects of human cytotrophoblast differentiation, invasion and migration. *Development* **127**:549-558, 2000
53. Meinhardt G, Husslein P, Knofler M: Tissue-specific and ubiquitous basic helix-loop-helix transcription factors in human placental trophoblasts. *Placenta* 26:527-539, 2005
54. Baczyk D, Kibschull M, Mellstrom B, et al: DREAM mediated regulation of GCM1 in the human placental trophoblast. *PLoS One* 8:e51837, 2013
55. Tyberghein K, Goossens S, Haigh JJ, et al: Tissue-wide overexpression of alpha-T-catenin results in aberrant trophoblast invasion but does not cause embryonic mortality in mice. *Placenta* 33:554-560, 2012
56. Imperatore A, Rolfo A, Petraglia F, et al: Hypoxia and preeclampsia: increased expression of urocortin 2 and urocortin 3. *Reprod Sci* 17:833-843, 2010
57. Knofler M, Pollheimer J: IFPA Award in Placentology lecture: molecular regulation of human trophoblast invasion. *Placenta* 33 Suppl:S55-62, 2012
58. Khong TY: The pathology of placenta accreta, a worldwide epidemic. *J Clin Pathol* 61:1243-1246, 2008
59. Read JA, Cotton DB, Miller FC: Placenta accreta: changing clinical aspects and outcome. *Obstet Gynecol* 56:31-34, 1980

60. Miller DA, Chollet JA, Goodwin TM: Clinical risk factors for placenta previa-placenta accreta. *Am J Obstet Gynecol* 177:210-214, 1997
61. Washecka R, Behling A: Urologic complications of placenta percreta invading the urinary bladder: a case report and review of the literature. *Hawaii Med J* 61:66-69, 2002
62. Wu S, Kocherginsky M, Hibbard JU: Abnormal placentation: twenty-year analysis. *Am J Obstet Gynecol* 192:1458-1461, 2005
63. Belfort MA: Indicated preterm birth for placenta accreta. *Semin Perinatol* 35:252-256, 2011
64. Publications Committee, Society for Maternal-Fetal Medicine, Belfort MA: Placenta accreta. *Am J Obstet Gynecol* 203:430-439, 2010
65. Bamberger AM, Makrigiannakis A, Röser K, et al: Expression of the high-mobility group protein HMGI(Y) in human trophoblast: potential role in trophoblast invasion of maternal tissue. *Virchows Arch* 443:649-654, 2003
66. Genbacev O, Larocque N, Ona K, et al: Integrin alpha4-positive human trophoblast progenitors: functional characterization and transcriptional regulation. *Hum Reprod* 31:1300-14, 2016
67. Wang X, Liu X, Li AY, et al: Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. *Clin Cancer Res* 17:2570-2580, 2011
68. Hetland TE, Holth A, Kaern J, et al: HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. *Virchows Arch* 460:505-513, 2012
69. Ding X, Wang Y, Ma X, et al: Expression of HMGA2 in bladder cancer and its association with epithelial-to-mesenchymal transition. *Cell Prolif* 47:146-151, 2014

Tables

Table 1: Summary of all samples investigated for the expression of *HMGA2*.

RQ: relative quantification; GA: calendar gestational age in weeks; n.a.: information not available; percentage of decidua: sample consisted of at least 50 % decidua; umbilical cord: sample contained a section of the umbilical cord; immunostaining: sample was used for immunostaining with an HMGA2-specific antibody. Staining extent: +- very weak. + weak. ++ moderate. +++ strong

age: age of the mother at delivery; sex: sex of the neonate; weight: weight of the neonate in grams; C section: Caesarean section

A: samples collected after abortion or stillbirth

B: samples collected after birth

Tab. 1A

case no.	RQ	GA	type of abortion	immunostaining	note
1	140.523	7	spontaneous		
2	9.902	7	spontaneous		percentage of decidua
3	3.120	15	induced		
4	95.469	9	spontaneous		
5	46.382	10	spontaneous		
6	68.581	8	spontaneous		
7	36.058	8	spontaneous		
8	32.201	8	induced		
9	29.015	8	spontaneous		
10	497.846	8	spontaneous	+++	
11	19.692	10	spontaneous		
12	89.261	9	spontaneous		
13	67.173	6	induced		
14	99.902	9	spontaneous		
15	19.433	14	spontaneous		
16	45.969	10	spontaneous		
17	49.632	7	n.a.		
18	141.657	10	spontaneous		
19	4.725	11	spontaneous		percentage of decidua
20	13.690	9	spontaneous		percentage of decidua
21	3.507	28	spontaneous		
22	130.567	7	spontaneous		
23	109.029	8	induced	++	
24	188.477	7	induced	+++	
25	9.020	10	spontaneous		
26	85.272	11	spontaneous		
27	55.483	8	spontaneous		
28	136.494	7	induced		
29	32.358	8	induced		
30	96.846	8	spontaneous		
31	64.117	7	spontaneous		
32	1.027	18	spontaneous		
33	23.595	22	spontaneous		part of umbilical cord
34	68.913	8	induced	+++	
35	244.977	8	spontaneous	+++	
36	23.640	10	spontaneous		
37	39.999	11	spontaneous		
38	24.045	9	spontaneous		

All rights reserved. No reuse allowed without permission.

39	2.220	20	induced		
40	1.057	32	spontaneous	+-	
41	198.117	9	spontaneous	+++	
42	87.735	7	induced	++	
43	26.091	8	spontaneous		
44	8.117	9	spontaneous		
45	54.529	9	spontaneous		
46	30.706	9	spontaneous		
47	9.355	7	spontaneous		percentage of decidua
48	80.126	8	spontaneous		
49	21.238	10	spontaneous		
50	44.867	9	spontaneous		
51	1.000	7	spontaneous		percentage of decidua
52	152.952	19	spontaneous	+	
53	63.482	7	spontaneous		
54	250.892	11	spontaneous		
55	15.773	7	induced		percentage of decidua
56	160.201	7	spontaneous		
57	247.132	11	spontaneous		
58	92.824	7	spontaneous		
59	74.893	9	spontaneous		
60	162.155	7	spontaneous		
61	126.681	6	induced		
62	186.271	9	spontaneous		
63	28.572	8	induced		
64	47.861	7	induced		
65	31.963	9	spontaneous		
66	154.653	7	spontaneous		
67	95.824	7	induced		
68	31.415	9	induced		
69	72.805	7	spontaneous		
70	56.650	10	spontaneous		
71	6.058	7	spontaneous		percentage of decidua
72	22.586	14	spontaneous		
73	123.656	7	induced		
74	28.452	9	spontaneous		
75	18.370	5	induced		percentage of decidua
76	20.153	7	induced		percentage of decidua
77	87.926	8	spontaneous		
78	109.971	12	spontaneous		
79	152.111	5	spontaneous		
80	128.672	7	spontaneous		
81	47.139	9	spontaneous		
82	3.306	28	n.a.		
83	4.502	30	n.a.		
84	23.446	27	spontaneous		
85	6.276	24	spontaneous		

Tab. 1B

case no.	RQ	GA	age	sex	weight	delivery	immunostaining
86	1.557	38	30	m	3155	spontaneous	
87	1.711	41	30	m	4250	C section	+-
88	1.525	38	41	m	3435	C section	+-
89	1.698	32	28	m	1750	C section	

Figures

Figure 1: *HMGA2* expression in relation to the gestational age. Linear display for *HMGA2* expression, all samples. Blue: spontaneous abortion, red: induced abortion, green: gathered postpartum, orange: abortion, no information available on type of abortion.

Figure 2: *HMGA2* expression in relation to the gestational age including the linear regression line with 95% confidence range. Logarithmic display for *HMGA2* expression, all samples. Coloring of the rhombi denotes the type of sample. Blue: spontaneous abortion, red: induced abortion, green: gathered after delivery, orange: abortion, no information available on the type of abortion.

Figure 3: Immunoreactivity for HMGA2.

In all but two cases the qRT-PCR data was in concordance with the interpretation of the HMGA staining. (A) Seven weeks calendar gestational age showing an intensive signal (red staining) for HMGA2 and a high expression as measured in the qRT-PCR. (B) Case no. 88 (38 weeks calendar gestational age) with a barely visible signal, the qRT-PCR showed a very low expression. In all samples that stained positive, HMGA2 was found in the nuclei of the stroma cells of the villi and, with a much weaker intensity, in the cytoplasm of the trophoblast.